CIK 0001400118 · <br>Emerging growth company
Sagimet Biosciences Inc.
Sign in to watch- Ticker
- SGMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205991472
- Phone
- (650) 561-8600
- Business address
- 950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
- Former names
- 3-V Biosciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-14 | Kemble George Director | Option exercise 10b5-1 | +326,618 | $6.36 | $2.1M | 388,779 |
| 2026-08-14 | Kemble George Director | Option exercise 10b5-1 | +24,369 | $6.36 | $155K | 413,148 |
| 2026-08-14 | Kemble George Director | Sale 10b5-1 | −350,987 | $10.23 | $3.6M | 62,161 |
| 2026-08-14 | Kemble George Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −326,618 | 31,455 | ||
| 2026-08-14 | Kemble George Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −24,369 | 11,608 | ||
| 2026-08-11 | Kemble George Director | Option exercise 10b5-1 | +9,751 | $6.36 | $62K | 71,912 |
| 2026-08-11 | Kemble George Director | Option exercise 10b5-1 | +10,455 | $6.36 | $66K | 82,367 |
| 2026-08-11 | Kemble George Director | Sale 10b5-1 | −20,206 | $9.95 | $201K | 62,161 |
| 2026-08-11 | Kemble George Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,751 | 358,073 | ||
| 2026-08-11 | Kemble George Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,455 | 35,977 | ||
| 2026-07-20 | Happel David President & CEO | Sale | −64,051 | $7.76 | $497K | 741,570 |
| 2026-07-20 | Rozek Elizabeth Chief Legal & Admin. Officer | Sale | −10,545 | $7.76 | $82K | 224,414 |
| 2026-07-20 | Kemble George Director | Sale 10b5-1 | −18,844 | $7.46 | $141K | 62,161 |
| 2026-06-12 | SEIDENBERG BETH C Director | Grant or award · Stock Option (Right to Buy) | +39,567 | 39,567 | ||
| 2026-06-12 | Hoelscher Paul W. Director | Grant or award · Stock Option (Right to Buy) | +39,567 | 39,567 | ||
| 2026-06-12 | Jarrett Jennifer Director | Grant or award · Stock Option (Right to Buy) | +39,567 | 39,567 | ||
| 2026-06-12 | GRAMMER ELIZABETH A Director | Grant or award · Stock Option (Right to Buy) | +39,567 | 39,567 | ||
| 2026-06-12 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +39,567 | 39,567 | ||
| 2026-06-12 | Phillips Anne M. Director | Grant or award · Stock Option (Right to Buy) | +39,567 | 39,567 | ||
| 2026-05-28 | Chauche Thierry Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 |
Page 1 of 10 · 194 trades